ETFS Holding Allergan, Inc.

 
ETF Quotes for ETFS Holding Allergan, Inc. top ^
  • Holdings: Johnson & Johnson , Pfizer Inc , Merck & Co Inc , Bristol-Myers Squibb Company , Allergan Inc ,
  • Morningstar Rating: 4 Stars
Sign-up for ihe investment picks
  • Holdings: E-mini S&P 500 Index Future Mar15 , MSCI EAFE Index Future Mar15 , Baker Hughes Inc , Allergan Inc , Covidien PLC ,
  • Morningstar Rating: 4 Stars
Sign-up for mna investment picks
  • Holdings: Edwards Lifesciences Corp , Vertex Pharmaceuticals Inc , Celgene Corp , CareFusion Corp , Allergan Inc ,
  • Morningstar Rating: 3 Stars
Sign-up for ryh investment picks
  • Holdings: AVANIR Pharmaceuticals Class A , Auxilium Pharmaceuticals Inc , Impax Laboratories Inc , Allergan Inc , Bristol-Myers Squibb Company ,
  • Morningstar Rating: 4 Stars
Sign-up for xph investment picks
  • Holdings: Staples Inc , Edwards Lifesciences Corp , Southwest Airlines Co , AmerisourceBergen Corp , Allergan Inc ,
  • Morningstar Rating: 4 Stars
Sign-up for fex investment picks
  • Holdings: Edwards Lifesciences Corp , Southwest Airlines Co , AmerisourceBergen Corp , Allergan Inc , Monster Beverage Corp ,
  • Morningstar Rating: 4 Stars
Sign-up for ftc investment picks
  • Holdings: Edwards Lifesciences Corp , Southwest Airlines Co , AmerisourceBergen Corp , Allergan Inc , Office Depot Inc ,
  • Morningstar Rating: 4 Stars
Sign-up for fad investment picks

 
Stock Quotes for Allergan, Inc. top ^
  • Industry: Drug Manufacturers - Specialty & Generic
  • Sector: Healthcare
  • Stock Style: Large Growth
  • Stock Type: Aggressive Growth
  • Morningstar Rating: 2 Stars
Sign-up for agn investment picks

 
News Articles for Allergan, Inc. top ^
Pershing Square Capital Management, L.P. (“Pershing Square”) and Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSX:VRX) (“Valeant”) announced an agreement with Allergan, Inc. (NYSE:AGN) (“Allergan”) to settle pending litigation before the Delaware Court of Chancery.
Sign-up for Pershing Square, Valeant and Allergan Settle Pending Litigation Before the Delaware Court of Chancery investment picks
Brokerage T.
Sign-up for T. Rowe Price urges Allergan to drop Salix bid investment picks
Allergan, Inc. (NYSE: AGN) (“Allergan” or the “Company”) today issued a statement regarding recent correspondence between Allergan and Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (“Valeant”) that was published by Valeant: Goldman, Sachs & Co.
Sign-up for Allergan Issues Statement Regarding Recent Valeant Correspondence investment picks
By Lauren Pollock and Chelsey Dulaney Valeant Pharmaceuticals International Inc. said it expects to report stronger-than-expected results for its third quarter and continued its push to bring Botox maker Allergan Inc. to the negotiating table as their takeover battle enters its fifth month.
Sign-up for Valeant offers olive branch to Allergan investment picks
Overall Same Store Organic Growth (unadjusted for generics) Expected to Exceed 15% in Third Quarter Bausch + Lomb Expected to Continue to Deliver Greater Than 10% Organic Growth (unadjusted) Valeant 3Q Results Expected to Beat Consensus on Revenue and Be Better than Guidance on Cash EPS, Organic Growth, Restructuring Charges and Adjusted Cash Flow from Operations Expect Continued Strong Double-digit Same Store Organic Growth in the Fourth Quarter Will Announce Third Quarter Results on October 20 LAVAL, Quebec , Sept.
Sign-up for Valeant Provides Update On Third Quarter Results And Sends Letter To Allergan CEO And Lead Independent Director investment picks
By David Benoit Activist investor William Ackman is threatening to sue Allergan Inc. if the Botox maker strikes a deal with Salix Pharmaceuticals Ltd.
Sign-up for Pershing threatens to sue Allergan if no holder vote held on Salix deal investment picks
By Jonathan D.
Sign-up for Botox maker Allergan rejected Actavis takeover bid investment picks
Allergan, Inc., (NYSE: AGN) announced today that the U.S. Food and Drug Administration (FDA) has approved OZURDEX® (dexamethasone intravitreal implant) 0.7 mg, a sustained-release biodegradable steroid implant, for the treatment of diabetic macular edema (DME). OZURDEX® was originally approved in June as a treatment for DME in adult patients who have an artificial lens implant (pseudophakic) or who are scheduled for cataract surgery (phakic). Based on ongoing review of clinical data demonstrating efficacy and safety, the FDA has now approved OZURDEX® for use in the general DME patient population.
Sign-up for Allergan Announces FDA Approves Revised Indication for OZURDEX® (dexamethasone intravitreal implant) 0.7 mg for the Treatment of Diabetic Macular Edema investment picks
The Board of Directors of Allergan, Inc. (NYSE: AGN) (“Allergan” or the “Company”) today issued the following statement: Goldman, Sachs & Co.
Sign-up for Allergan Board of Directors Issues Statement investment picks
Allergan, Inc. (NYSE: AGN) today provided the following updates on earnings per share (EPS) and sales expectations based on current information.
Sign-up for Allergan Provides Update on Earnings Per Share and Sales Expectations investment picks
Valeant Pharmaceuticals International Inc. (VRX) and partner Pershing Square Capital Management plan to boost their bid for Allergan Inc. (AGN) by $15 a share, The Wall Street Journal reported late Tuesday, citing unnamed sources.
Sign-up for Valeant to boost Allergan bid by $15 a share: report investment picks
By Russ Britt, MarketWatch LOS ANGELES (MarketWatch) -- While Valeant says that it handily beat analyst estimates for the third quarter, its current acquisition target, Botox maker Allergan Inc., offered its own take on the results.
Sign-up for UPDATE: Allergan files rebuttal to Valeant earnings investment picks

Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
ETFS Holding Allergan, Inc.
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: ETFS Holding Allegheny Technologies Inc  |  Next: ETFS Holding Allete, Inc.